# Controlled Author Corrections Report: HBB Mutation Analyzer Manuscript

> **Project:** HBB Gene Mutation Analyzer Research Project  
> **Document Title:** CONTROLLED AUTHOR CORRECTIONS REPORT  
> **Target Manuscript:** `research/manuscript/PHASE5_4_FINAL_MANUSCRIPT_DRAFT.md`  
> **Execution Mode:** Controlled Scientific Correction Pass (Strictly Narrow Scope)  
> **Date:** 2026-10-11  
> **Status:** COMPLETED — Zero Protected Artifacts Modified  

---

## 1. Executive Summary

In accordance with strict author guidance, a controlled correction pass was executed on the primary manuscript draft (`research/manuscript/PHASE5_4_FINAL_MANUSCRIPT_DRAFT.md`). All changes were strictly restricted to the approved scopes identified in `research/results/FINAL_MANUSCRIPT_CONSISTENCY_AUDIT.md`.

### Core Adherence Checklist:
- **Zero Benchmarks Rerun:** The computational benchmark was not executed or rerun.
- **Zero Protected Files Altered:** Source code, reference FASTA/JSON files, frozen manifests, benchmark results, the comparison engine, the decision matrix, and the benchmark protocol were untouched.
- **Zero Numerical Values Modified:** Denominators ($N = 55$), primary molecular concordance (55/55, 100.00%, CI: [93.51%, 100.00%]), category counts (30, 20, 5), protein match counts (28, 20, 5, 2), and synthetic robustness rejections (18/18, 100.00%, CI: [81.47%, 100.00%]) remain identical.
- **Zero Inventions:** No author identities, institutional affiliations, ORCIDs, funding sources, grant numbers, repository URLs, or Zenodo DOIs were invented or asserted. Clearly labeled placeholders were established for author completion.
- **Full Scientific Limitations Preserved:** All disclosures of incorporation/verification bias, ClinVar-only provenance, zero non-ClinVar corroboration, unrepresented mutation classes ($n = 0$), and the separation of molecular consequence from clinical pathogenicity remain intact.

---

## 2. Itemized Manuscript Changes (Before & After Text)

### Change 1: Author Metadata Placeholders (Header)
- **Manuscript Section:** Title Header (Lines 1–9)
- **Before Text:**
  ```markdown
  # Concordance Evaluation of Deterministic HBB Molecular Consequence Prediction Against a Curated ClinVar-Derived External Annotation Reference

  ---

  ## Abstract
  ```
- **After Text:**
  ```markdown
  # Concordance Evaluation of Deterministic HBB Molecular Consequence Prediction Against a Curated ClinVar-Derived External Annotation Reference

  **[Author Name(s) Placeholder — To be determined by Authors]**  
  *[Institutional Affiliation(s) Placeholder — To be determined by Authors]*  
  *[Corresponding Author Contact Placeholder — To be determined by Authors]*  
  *[ORCID Identifier(s) Placeholder — To be determined by Authors]*  

  ---

  ## Abstract
  ```
- **Scientific Rationale:** Establishes standard front-matter placeholders without fabricating author names, affiliations, or contact credentials.

---

### Change 2: Historical Reference Transcript Attribution (Methods Section 2.2)
- **Manuscript Section:** Methods — Section 2.2 ("Reference Sequence and Transcript Model", Line 100)
- **Before Text:**
  ```markdown
  In certain historical annotations and literature summaries, Exon 3 is described as spanning 261 bp with a 132 bp 3' UTR (yielding a 626 bp spliced transcript, $c.*1..c.*132$); the project implementation and versioned RefSeq reference files (`NM_000518.5.json` and `NM_000518.5.fasta`) explicitly incorporate the 628 bp reference model ($c.*1..c.*134$).
  ```
- **After Text:**
  ```markdown
  Under predecessor NCBI RefSeq record `NM_000518.4` (in effect February 11, 2003 until June 13, 2018) and associated historical literature, Exon 3 was annotated as spanning 261 bp with a 132 bp 3' UTR (yielding a 626 bp spliced transcript, $c.*1..c.*132$ terminating at `...TTCATTGC`); the updated RefSeq `NM_000518.5` standard and project reference files (`NM_000518.5.json` and `NM_000518.5.fasta`) explicitly incorporate the 628 bp reference model ($c.*1..c.*134$), reflecting the addition of two terminal adenines (`AA` at positions 627–628 supported by full-length cDNA clone BU661647.1).
  ```
- **Scientific Rationale:** Accurately grounds the historical 626 bp / 132 bp UTR model in its official NCBI RefSeq predecessor record (`NM_000518.4`), documenting the exact biological basis (two terminal adenines from cDNA BU661647.1) for the version 5 refinement.

---

### Change 3: Reference Model Clarification in Table 1 (Results Section 3.2)
- **Manuscript Section:** Results — Section 3.2 (Table 1, Row 5)
- **Before Text:**
  ```markdown
  | **Syntax / Reference Rejections** | 0 | 0.00% | [0.00%, 6.49%] | All 55 variants valid under `NM_000518.5` |
  ```
- **After Text:**
  ```markdown
  | **Syntax / Reference Rejections** | 0 | 0.00% | [0.00%, 6.49%] | All 55 variants valid under canonical reference models (exonic/UTR against `NM_000518.5`, intronic against `NG_000007.3`) |
  ```
- **Scientific Rationale:** Correctly reflects that the 5 canonical splice acceptor variants (Class C09) validate their intronic reference bases against genomic reference `NG_000007.3`, while exonic/UTR variants validate against spliced transcript `NM_000518.5`.

---

### Change 4: Declarations and End-Matter Placeholders
- **Manuscript Section:** End-Matter — Section 8 ("Declarations and Author Information")
- **Before Text:**
  *Section did not exist in draft.*
- **After Text:**
  ```markdown
  ---

  ## 8. Declarations and Author Information

  ### Author Details
  - **Authors:** [AUTHOR PLACEHOLDER: Full author names, institutional affiliations, and ORCID identifiers to be provided by authors]
  - **Corresponding Author:** [CORRESPONDING AUTHOR PLACEHOLDER: Name and institutional email address to be provided by authors]

  ### Ethics Approval and Consent to Participate
  [ETHICS PLACEHOLDER: Formal institutional ethics determination or IRB statement to be provided by authors. Do not assert exemption without institutional or journal confirmation.]

  ### Consent for Publication
  [CONSENT PLACEHOLDER: Author declaration regarding publication consent to be confirmed according to target journal guidelines.]

  ### Competing Interests
  [COMPETING INTERESTS PLACEHOLDER: Formal conflict of interest declaration to be provided by authors.]

  ### Funding
  [FUNDING PLACEHOLDER: Funding sources and grant numbers to be inserted by authors, or declaration that no external funding was received.]

  ### Authors' Contributions
  [CONTRIBUTIONS PLACEHOLDER: Detailed CRediT statement of author contributions to be provided by authors.]

  ### Acknowledgements
  [ACKNOWLEDGEMENTS PLACEHOLDER: Colleague, laboratory, and institutional acknowledgements to be added by authors.]

  ### Data and Code Availability
  [DATA/CODE AVAILABILITY PLACEHOLDER: Verified public repository URLs, Zenodo DOI archive links, and ClinVar accession references to be confirmed and inserted by authors prior to submission.]
  ```
- **Scientific Rationale:** Establishes necessary academic declarations with transparent placeholders, strictly avoiding unconfirmed assertions of ethics exemption, public repository availability, or funding.

---

## 3. Consistency Audit Across All Manuscript Sections

Every occurrence of numerical counts and biological classifications was re-audited across the modified manuscript draft:

| Metric / Classification | Manuscript Value | Abstract | Results 3.2 | Table 2 (3.3) | Table 3 (3.4) | Table 5 (3.7) | Discussion 4.1 | Limitations 5.4 |
|---|:---:|:---:|:---:|:---:|:---:|:---:|:---:|:---:|
| **Primary Cohort Denominator** | **55** | L14 | L209 | L238 | L268 | L310 | L320 | L370 |
| **Primary Molecular Matches** | **55 (100.00%)** | L17 | L209 | — | L268 | L310 | L320 | — |
| **Primary Clopper-Pearson CI** | **[93.51%, 100.00%]** | L17 | L209 | — | L268 | L310 | L320 | — |
| **`EXACT_MOLECULAR_AGREEMENT`** | **30 (54.55%)** | L17 | L221 | — | — | — | L323 | — |
| **Protein MATCH (Exact)** | **28 (50.91%)** | L17 | L221 | L234 | — | L311 | L323 | L387 |
| **Protein NOT_APPLICABLE** | **2 (3.64%)** | L17 | L221 | L237 | — | — | L323 | — |
| **Protein Representation Diff** | **20 (36.36%)** | L17 | L222 | L235 | — | L311 | L324 | L387 |
| **Protein Incomplete (Splice)** | **5 (9.09%)** | L17 | L223 | L236 | — | L311 | L325 | L387 |
| **Synthetic Controls Denominator** | **18** | L17 | — | — | — | L312 | L327 | — |
| **Synthetic Rejections** | **18 (100.00%)** | L17 | — | — | — | L312 | L327 | — |
| **Synthetic Clopper-Pearson CI** | **[81.47%, 100.00%]** | L17 | — | — | — | L312 | L327 | — |
| **Software Regression ($A == B$)** | **55 / 55 (100.00%)** | L17 | — | — | — | L313 | L327 | — |

**Consistency Finding:** All counts are mathematically harmonious ($28 + 20 + 5 + 2 = 55$; $28 + 2 = 30$). Zero conflation between the 30 molecular agreements and 28 protein matches exists anywhere in the text.

---

## 4. Cryptographic Recalculation & Protected Artifact Integrity

All protected research artifacts were recalculated using SHA256 and compared against pre-recorded baselines:

| Protected Artifact | Local File Path | Baseline SHA256 Checksum | Recalculated SHA256 Checksum | Verification Result |
|---|---|---|---|:---:|
| **Primary Dataset Manifest** | `research/manifest/phase2c_primary.json` | `39eb60de0e60dea8a76f2290912905b197fb1a04b738f72b0493bcdab2e0eb96` | `39eb60de0e60dea8a76f2290912905b197fb1a04b738f72b0493bcdab2e0eb96` | **INTACT (100% MATCH)** |
| **Historical Test Manifest** | `research/manifest/frozen_test.json` | `2f6b88422b82d3f74c20f00985a34ffb5c1c78c311e4d8b584bc732cf5fc5994` | `2f6b88422b82d3f74c20f00985a34ffb5c1c78c311e4d8b584bc732cf5fc5994` | **INTACT (100% MATCH)** |
| **Benchmark Protocol** | `research/protocol/PHASE2C_BENCHMARK_PROTOCOL.md` | `e4bad0a095cdfa8112a649f3d8a0794cf0078d218611bb965020b100ba368969` | `e4bad0a095cdfa8112a649f3d8a0794cf0078d218611bb965020b100ba368969` | **INTACT (100% MATCH)** |
| **Candidate Benchmark Results** | `research/results/phase2c_benchmark_candidate_results.json` | `e0493b36b95c75b7034ff37f30aaa393dcaaa9f7252fc171ec6b20db29a766c4` | `e0493b36b95c75b7034ff37f30aaa393dcaaa9f7252fc171ec6b20db29a766c4` | **INTACT (100% MATCH)** |
| **Benchmark Summary Record** | `research/results/phase2c_benchmark_summary.json` | `36047f0675a86ccf2032f42624ce2f48c16636ba37ca2bf15607376c533b8718` | `36047f0675a86ccf2032f42624ce2f48c16636ba37ca2bf15607376c533b8718` | **INTACT (100% MATCH)** |
| **Pure Sequence: NM_000518.5** | `data/reference/NM_000518.5.fasta` (seq only) | `9e811fb12c639fc6610265da635ebbf31521b62410132c6e19dfd0192bd194f3` | `9e811fb12c639fc6610265da635ebbf31521b62410132c6e19dfd0192bd194f3` | **INTACT (100% MATCH)** |
| **Pure Sequence: NG_000007.3** | `data/reference/NG_000007.3.fasta` (seq only) | `6de4b3877f2d21cd0e97f69341be065e3a16fb3b737379a12c7b54db41211c18` | `6de4b3877f2d21cd0e97f69341be065e3a16fb3b737379a12c7b54db41211c18` | **INTACT (100% MATCH)** |

---

## 5. Author Action Checklist Prior to Journal Submission

The manuscript draft is now textually and scientifically consistent. Before journal submission, the authors must address the following administrative items:

- [ ] **Author List & Affiliations:** Replace `[AUTHOR PLACEHOLDER]` in the header and Section 8 with author names, institutional departments, institutions, cities, countries, and ORCID identifiers.
- [ ] **Corresponding Author:** Replace `[CORRESPONDING AUTHOR PLACEHOLDER]` with the designated corresponding author's name and institutional email address.
- [ ] **Ethics Determination:** Replace `[ETHICS PLACEHOLDER]` with the institution's formal IRB status or confirmation of exemption for de-identified secondary database analysis.
- [ ] **Funding:** Replace `[FUNDING PLACEHOLDER]` with applicable grant numbers or the statement: *"This research received no external funding."*
- [ ] **Competing Interests:** Replace `[COMPETING INTERESTS PLACEHOLDER]` with financial and non-financial declarations or: *"The authors declare that they have no competing interests."*
- [ ] **Data and Code Availability:** Replace `[DATA/CODE AVAILABILITY PLACEHOLDER]` with the confirmed GitHub repository URL and permanent Zenodo DOI archive link once established.
- [ ] **Target Journal Formatting:** Verify journal-specific requirements (abstract word limit, heading numbering style, and reference citation syntax).

---

## 6. Final Status Finding

```
================================================================================
FINAL DETERMINATION:
• CORRECTIONS COMPLETE, PROTECTED ARTIFACTS UNCHANGED
================================================================================
```

The controlled corrections pass has successfully harmonized the manuscript draft with official RefSeq accessions and research artifacts. All numerical results, frozen datasets, benchmark outputs, and scientific conclusions remain strictly intact and verified.
